Skip to content
Tokyo Brief東 京 ブ リ ー フJapan's day, wrapped and delivered by morning.

DealsPharma & Healthcare

Shionogi closes IntraBio purchase, adding a drug with a new US ataxia approval

Shionogi has completed its purchase of IntraBio and now owns AQNEURSA, which the FDA approved in September 2026 as the first treatment for ataxia in A-T, while a European review of that use is still open.

By Tokyo Brief DeskNov 18, 2026, 10:01 JST2 min readShionogi & Co.,Ltd.4507
An amber medicine bottle and a small dosing syringe on a laboratory bench beside a molecular diagram, evoking a rare-disease drug.

Shionogi said on 18 November 2026 that its US group company, Shionogi Inc., has completed the acquisition of IntraBio Inc., the Texas-based maker of AQNEURSA. The deal makes IntraBio a wholly owned subsidiary, as announced on 5 October. Earlier Tokyo Brief coverage

What Shionogi now owns

AQNEURSA treats the neurological symptoms of Niemann-Pick disease type C (NPC). The US Food and Drug Administration approved it in September 2024 for adults and children weighing 15kg or more. The European Medicines Agency approved it in January 2026 for patients weighing 20kg or more.

The newer prize is ataxia in ataxia-telangiectasia (A-T). In September 2026 the FDA approved AQNEURSA for the ataxia of A-T patients weighing 15kg or more, which Shionogi describes as the first and only treatment for that use. The EMA is still reviewing the A-T application.

IntraBio had also started a randomized, placebo-controlled, double-blind, crossover phase 3 trial in CACNA1A-related disorders. Shionogi said it will continue that programme and will consider AQNEURSA's potential in other rare diseases.

Fit with Shionogi's rare-disease push

Shionogi says that since it acquired the global rights to the ALS drug RADICAVA (edaravone) in April 2026, it has accumulated expertise in neurodegenerative disease and built sales and medical-affairs foundations in rare disease, and that IntraBio adds to them. Its rare-disease pipeline includes clinical programmes in Pompe disease, fragile X syndrome and Jordan's syndrome, plus early-stage programmes in other rare neurodegenerative diseases.

Shionogi's chief executive said the deal adds AQNEURSA to the portfolio and brings new rare-disease expertise. The founder of the A-T Children's Project and the executive director of the National Niemann-Pick Disease Foundation also welcomed the deal in statements included in the release, both voicing hope that working with Shionogi would widen patient access.

Financial effect

Shionogi says the effect on consolidated results for the year ending March 2027 is already built into the revised forecast it published on 29 October 2026. The closing notice does not restate the purchase price or give a revenue figure for AQNEURSA.